Skip to content

Negative Pressure Wound Therapy in Groin Dissection

A Randomised Controlled Trial Comparing PICO™ Single Use Negative Pressure Wound Therapy System (Smith & Nephew Healthcare Limited, UK) to Conventional Wound Care Following Inguinal Lymphadenectomy for Metastatic Cutaneous Malignancy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02408835
Enrollment
22
Registered
2015-04-06
Start date
2015-07-31
Completion date
2019-07-31
Last updated
2015-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm Metastasis, Non-healing Surgical Wound (Disorder), Secondary Malignant Neoplasm of Lymph Node, Skin Neoplasms

Keywords

negative pressure wound therapy, lymphadenectomy, wound healing

Brief summary

This study investigates the use of a negative pressure wound therapy device (PICO™, Smith & Nephew Healthcare, UK) on clean, closed surgical wounds, in patients who are undergoing inguinal lymphadenectomy for metastatic carcinoma of cutaneous origin.

Detailed description

Patients may develop inguinal lymph node metastases from a variety of cutaneous neoplasms. A number of factors conspire to cause a high rate of wound breakdown and other complications in this patient group. Reported rates of wound healing complications vary in the literature, but tend to affect \> 40% of patients. A new negative pressure wound therapy device is recommended for use in clean, closed surgical wounds (PICO™ system, Smith & Nephew Healthcare, UK). Patients will be randomised to receive either PICO™ system for up to seven days, or conventional dressings, and then assessed for wound healing and other outcome measures.

Interventions

DEVICEPICO™

Negative pressure wound therapy device for closed surgical wounds.

Sponsors

South Eastern Health and Social Care Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically- or cytologically-proven inguinal lymph node metastases from neoplasm of cutaneous origin

Exclusion criteria

* inability to give informed consent for participation

Design outcomes

Primary

MeasureTime frameDescription
Time to wound healingFrom date of surgery until epithelial integrity is restored at the surgical site. Assessed at least weekly until wound is healed, up to 20 weeks after surgeryDetermination of wound healing

Secondary

MeasureTime frameDescription
Wound infection As defined by Comprehensive Complication Index (CCI)From date of surgery until wound is healed (epithelial integrity restored at surgical site), up to 20 weeks after surgery.As defined by Comprehensive Complication Index (CCI)
Lymphoedema (Limb volume measurements)From date of surgery up to one year post-operatively.Limb volume measurements at 3, 6, 9 and 12 months
Need for further surgical interventions to achieve wound healingFrom date of surgery until wound is healed, up to 20 weeks after surgery.
Scar appearance (POSAS)From date of surgery up to one year post-operatively.POSAS at 3,6, 9 and 12 months
Patient reported outcomes (qualitative interview)From date of surgery to six months post-operatively.Semi-structured qualitative interviews in first week after surgery, and at 6 months after surgery.

Countries

United Kingdom

Contacts

Primary ContactSandra E McAllister, MD
s.mcallister@qub.ac.uk02890484511
Backup ContactChristopher Hill, MB
02890484511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026